Vetnews | September 2025 12 « BACK TO CONTENTS Oxidised Mannan: A Novel Adjuvant Candidate for Enhancing Immune Responses in Veterinary Rabies Vaccine Rajab Mardani1, Anahita Bahmanje1, Yousef Cheraghi Kazeroni1, Fereydoon Khoshroo1, Bahram Roshanaie2, Tahereh Sadeghche3, Kourosh Pajaie3, Seyed Nezamedin Hosseini4, Delaram Doroud4,*, and Maryam Shahali1,* Departments of 1Viral Vaccines Production, 2Quality Control, and 3Hepatitis B Vaccine Production, Research and Production Complex, Pasteur Institute of Iran, 4Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran Rabies continues to pose a serious public health threat worldwide, with vaccination being the most effective means of prevention. However, commercially available inactivated rabies vaccines often require multiple doses and lack potent adjuvants to enhance their efficacy. This study aimed to investigate the coupling of whole inactivated rabies virus to mannan under oxidising conditions to improve immune responses against a standard rabies vaccine. We explored the conjugation of whole inactivated rabies virus with oxidised mannan (Rab-OxMan) to enhance immune responses. Mice were immunised intraperitoneally with 350 µg of the Rab-OxMan formulation on days 1 and 7. Two weeks after immunisation, serum samples were collected to measure levels of IgG, IgM, and TNF-a using ELISA. The vaccine’s potency was also evaluated using the National Institutes of Health (NIH) assay. Our findings showed a significant increase in IgG levels and a decrease in IgM levels in the Rab-OxMan group compared to the Alumadjuvanted vaccine group (p<0.05). Additionally, TNF-α levels were notably higher in the Rab-OxMan group (p<0.05). Statistical analysis revealed that IgG levels had the highest sensitivity and specificity, with a significant correlation between the measured variables. Importantly, the Rab-OxMan formulation provided 1.8 times greater protection in challenge tests compared to the alum-adjuvanted group. This study is the first to demonstrate that oxidised mannan can serve as a novel adjuvant for veterinary rabies vaccines. The results highlight significant improvements in the immunogenicity and efficacy of rabies vaccines, suggesting a promising strategy for enhancing rabies prevention and potentially reducing the incidence of this deadly disease. INTRODUCTION Rabies is one of humanity’s oldest infectious diseases. The virus claims approximately 60,000 human lives annually and also causes an economic loss of 8.6 billion USD per year globally.1 An estimated number of 10 million people receive post-exposure treatments each year after being exposed to animals suspected to be infected with rabies.2
RkJQdWJsaXNoZXIy OTc5MDU=